<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738229</url>
  </required_header>
  <id_info>
    <org_study_id>Valtrex for HGS</org_study_id>
    <nct_id>NCT02738229</nct_id>
  </id_info>
  <brief_title>Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children?</brief_title>
  <official_title>Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children? A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Association of Emergency Physicians</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary herpetic gingivostomatitis is a frequent problem in pediatrics. Complications of this
      are dehydration, pain and hospitalisation. The objective of this randomized controlled trial
      is to assess the clinical efficacy of oral Valacyclovir to decrease the duration of symptoms
      associated with acute herpes gingivostomatitis in children. This study will involve 80
      children aged 1 to 8 years old to receive weight adjusted doses of valacyclovir for 7 days.
      The primary outcome measure will be the duration (in days) of feeding and/or drinking
      difficulties.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of feeding and/or drinking difficulties</measure>
    <time_frame>2 weeks</time_frame>
    <description>This will be defined by the number of days until the participants return to normal feeding and eating according to the parents.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of fever</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of pain</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of oral lesions</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global parent satisfaction</measure>
    <time_frame>2 weeks</time_frame>
    <description>Likert scale on how satisfied the parents are with the medication. This will be measured during a follow-up survey at 7 and 14 days following randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of school or work absence</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>utilisation of medical resources</measure>
    <time_frame>2 weeks</time_frame>
    <description>hospitalisation for intra venous hydration, visit to a physician, use of analgesics or other medication. This will be measured during a follow-up survey at 7 and 14 days following randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse side effects</measure>
    <time_frame>2 weks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Herpetic Gingivostomatitis</condition>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valacyclovir will be given twice a day with following doses according to weight:
10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <arm_group_label>Valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria are :

          -  Children from 10 to 28 Kg of weight. The inclusion of participants is based on weight
             for practical/feasibility reasons because the study medication will be provided in
             tablet format. The lower limit of 10 kg is to limit to three strata of weight and
             limit costs engendered by the preparation of medication.

          -  Clinical diagnosis of herpetic gingivostomatitis according to the treating physician.
             This is described by the presence of:

               -  Fever (&gt;38.5° rectal, &gt;38° oral) AND

               -  Vesicular or ulcerative lesions located in the anterior of the mouth

               -  Associated or not with perioral vesicular lesions Visiting the emergency
                  department within the first 96 hours of the disease begin.

        Exclusion criteria are :

          -  Duration of fever &gt; 4 days

          -  Hospitalised patients

          -  Immunocompromised patients

          -  Patients with known hypersensitivity to Valacyclovir

          -  Patients with renal failure

          -  Children with complete incapacity of oral treatment intake

          -  Unable to be contacted for phone follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathalie Lucas, MD</last_name>
    <phone>514-345-4931</phone>
    <email>lucasnath@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jocelyn Gravel, MD</last_name>
    <phone>514-345-4931</phone>
    <phone_ext>2559</phone_ext>
    <email>graveljocelyn@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyn Gravel, MD</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>2559</phone_ext>
      <email>graveljocelyn@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Weill Olivia, MD</last_name>
      <phone>514-345-4931</phone>
      <email>weill.olivia@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jocelyn Gravel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucas Nathalie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud Christian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tonson-LaTour Aude, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roy Hélène, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Jocelyn Gravel</investigator_full_name>
    <investigator_title>MD, MSc, FRCPC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Stomatitis, Herpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

